Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
July 12 2021 - 4:05PM
Business Wire
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the
appointment of Dr. Ronit Simantov to its Board of Directors,
effective today.
“I am very pleased to welcome Dr. Ronit Simantov to the Clovis
Oncology Board of Directors, as she brings a wealth of expertise in
oncology research and drug development to the role,” said Patrick
J. Mahaffy, President and CEO of Clovis Oncology. “Dr. Simantov’s
extensive background and experience will support Clovis’ key
strategic priorities as we continue to advance both Rubraca’s
pipeline into a potentially broader label and the Company’s
early-stage pipeline of targeted radiotherapy candidates, including
FAP-2286, into clinical development.”
Dr. Simantov has served as chief medical officer of Gamida Cell
Ltd. since July 2017. Prior to joining Gamida Cell, Dr. Simantov
served as vice president, Oncology Global Medical Affairs at Pfizer
Inc., where she was responsible for multiple oncology programs in
various roles from 2011 to June 2017. Prior to Pfizer, Dr. Simantov
served as vice president of clinical research at OSI
Pharmaceuticals, as chief medical officer at CuraGen Corporation
(acquired by Celldex) where she led development of small molecules
and antibody-drug conjugates, and at Bayer HealthCare
Pharmaceuticals, where she led the phase 3 study of Nexavar®
(sorafenib) resulting in the first approval of a tyrosine kinase
inhibitor in renal cell carcinoma. Prior to joining industry, Dr.
Simantov spent seven years on the academic faculty at Weill Medical
College of Cornell University, where she directed the fellowship
program and conducted angiogenesis and vascular biology research.
She has authored over 40 peer-reviewed manuscripts. Dr. Simantov
holds an M.D. from New York University School of Medicine and a
B.A. from Johns Hopkins University. She completed a residency in
internal medicine at New York Hospital Cornell Medical Center, and
a fellowship in hematology and oncology at Weill Cornell Medicine.
We believe that Dr. Simantov possesses specific attributes that
qualify her to serve on our board of directors, including her
clinical development and research background in the field of
oncology, as well as her expertise reflected in her academic
experience and scientific and medical journal publications.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on
acquiring, developing and commercializing innovative anti-cancer
agents in the U.S., Europe and additional international markets.
Clovis Oncology targets development programs at specific subsets of
cancer populations, and simultaneously develops, with partners, for
those indications that require them, diagnostic tools intended to
direct a compound in development to the population that is most
likely to benefit from its use. Clovis Oncology is headquartered in
Boulder, Colorado, with additional office locations in the US and
Europe. Please visit www.clovisoncology.com for more
information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210712005776/en/
Anna Sussman 303.625.5022 asussman@clovisoncology.com
Breanna Burkart 303.625.5023 bburkart@clovisoncology.com
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Apr 2023 to Apr 2024